The FRQs include consideration of comprehensive cancer genome profiling (CGP) tests, ET after CDK4/6 inhibitor therapy, adjuvant therapy for small tumors without lymph node metastasis, and systemic therapy for elderly patients. The gene discussed is CDK4; the disease is metastatic malignant neoplasm in the lymph nodes.